-
Under the "involvement" of the domestic generic drug market, the "going abroad" of pharmaceutical companies is accelerating
Time of Update: 2023-01-01
It is worth mentioning that this year, Hengrui Pharmaceutical's contrast agent generic drug ANDA has obviously bloout, and the company's gadoterate glucosamine injection and iodixanol injection ANDA have also been approved by the FDA in April-May. Among them, iodixanol injection has also become the first generic drug in the US market, enjoying a 180-day market exclusivity period; According to the data, the global sales of iodixanol injection-related dosage forms are about 873 million US dollars.
-
Three pharmaceutical companies join forces to accelerate the commercialization of new antidepressant drugs!
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];On November 3 this year, Luye Pharmaceutical announced that its self-developed class 1 innovative drug toludi venlafaxine hydrochloride sustained-release tablets (trade name: Ruoxinlin) was officially approved by the National Medical Products Administration for the treatment of depression.
-
Targeted drugs are too expensive to use? The industry calls for more targeted drugs to enter medical insurance
Time of Update: 2023-01-01
The industry calls for more targeted drugs into medical insurance (Image source: Pharmaceutical Network) In recent years, with the flow of targeted drugs and immune drugs into the market, patients have brought new means and new hopes for treatment, but the price of targeted drugs is often expensive, and many patients' families face the burden of expensive drug costs, and can only look forward to drugs.
-
$5 billion! This domestic blockbuster FIC new drug license out
Time of Update: 2023-01-01
Akeso announced on December 6 that the company's second potential global FIC dual antibody product Evosi (PD-1/VEGF bispecific antibody) license out, Akeso will grant Summit Therapeutics exclusive license rights to develop and commercialize the product in the United States, Canada, Europe and Japan, and retain the development and commercialization rights of Evosil except in the above regions, including China.
-
Daan Gene took the initiative to apply for a price reduction, or open a price war in the molecular diagnostic industry!
Time of Update: 2023-01-01
Recently, the centralized procurement platform for drugs and medical consumables in Gansu Province issued a notice that after receiving an application from an enterprise, 97 of the 53 registration certificates of the external diagnostic reagent products took the initiative to apply for a price reduction (Daan Gene), of which 12 new declaration registration certificates were reviewed and passed in accordance with the "green channel".
-
Local pharmaceutical companies are actively expanding the European biopharmaceutical market
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];With the improvement of the R&D strength of domestic innovative pharmaceutical enterprises and the intensification of the "involution" of the domestic pharmaceutical market, going global will become one of the important layouts for the sustainable development of local pharmaceutical companies.
-
Recently, many pharmaceutical companies are frequently experiencing shareholder reductions
Time of Update: 2023-01-01
Like Teyi Pharmaceutical, on November 15, BrightPharma also issued an announcement that its major shareholder Zhong Weifang plans to reduce its shares in the company through block transactions within 3 months after 3 trading days from the date of disclosure of this announcement, and the total number of shares to reduce will not exceed 2% of the company's total share capital, that is, no more than 8.
-
Good news has spread in the injection industry, and a number of new drugs have been approved for clinical trials
Time of Update: 2023-01-01
, a wholly-owned subsidiary of the company, has recently received the "Drug Registration Certificate" for ambroxol hydrochloride injection approved and issued by the State Medical Products Administration.
-
Note that these acts of producing medical devices will be punished! Some companies were fined millions of dollars
Time of Update: 2023-01-01
Recently, a news disclosed on the website of the Shenzhen Market Supervision Bureau that a company was fined more than 160,000 yuan for producing Class II medical devices that did not meet the technical requirements of the product attracted attention and heated discussions in the industry.
-
Domestic pharmaceutical companies "went overseas" to lock in the European market, and Fosun, Baekje, Junshi and others broke through
Time of Update: 2023-01-01
Going overseas is an important way for innovative pharmaceutical companies to explore new business growth points, and it is an inevitable trend for innovative biopharmaceutical companies to go overse
-
Hubei issued a notice to standardize the commercial marketing of medical beauty to crack down on market chaos
Time of Update: 2023-01-01
(End) On December 1, the Hubei Provincial Administration for Market Regulation issued a notice regulating the commercial marketing behavior of medical cosmetology, safeguarding the order of the medical cosmetology market and the legitimate rights and interests of consumers.
-
Over 1000 bits! What signal does the departure of executives of listed pharmaceutical companies send?
Time of Update: 2023-01-01
(Image source: Pharma Network) Flush data shows that as of November 17, more than 1,400 executives in the A-share biomedical industry left the year, involving 357 enterprises.
-
The purchase price exceeds $20 billion! Who will this rare disease company "spend"
Time of Update: 2023-01-01
It is understood that Horizon Therapeutics, an innovative pharmaceutical company for rare diseases, announced on November 30 that it was conducting preliminary negotiations with Amgen, Johnson & Johnson (Janssen) and Sanofi on a potential acquisition offer.
-
The culture media industry is growing rapidly, and the trend of domestic substitution is accelerating
Time of Update: 2023-01-01
63 billion yuan, and the CAGR of China's cell culture media market is expected to be 22.
63 billion yuan, and the CAGR of China's cell culture media market is expected to be 22.
-
34 pharmaceutical and biological companies were investigated by institutions, and 10 shares were investigated by more than 20 institutions
Time of Update: 2023-01-01
Among them, the domestic IVD company Dirui Medical has attracted a lot of institutional attention, in the past 5 trading days (November 29 to December 5), a total of 143 institutions have been surveyed, and the new closing price of the stock is 26.
-
The traditional Chinese medicine sector has risen significantly, and this individual stock has risen 8 times in the past year
Time of Update: 2023-01-01
It is understood that Guizhou Bailing is a hot stock of CAR-T therapy, traditional Chinese medicine, and innovative drug concept.
It is understood that Guizhou Bailing is a hot stock of CAR-T therapy, traditional Chinese medicine, and innovative drug concept.
-
To accelerate innovative R&D, healthcare companies are starting a wave of financing
Time of Update: 2023-01-01
(hereinafter referred to as "Yangqi Medical Core") has obtained tens of millions of yuan in angel round financing led by Yuansheng Venture Capital and co-invested by old shareholder Sequoia China Seed Fund.
-
Under the "hoarding tide", ibuprofen production enterprises have attracted the attention of institutions and investors
Time of Update: 2023-01-01
Rundu shares Rundu replied to investors on November 15 that the company's product ibuprofen sustained-release capsules are suitable for relieving mild to moderate pain such as headache, joint pain, migraine, toothache, muscle pain, neuralgia, and dysmenorrhea.
-
Pharmaceutical companies have set off a "wave of cooperation", involving new drug research and development, commercialization...
Time of Update: 2023-01-01
Becton Medical has joined forces with NanoString On December 1, medical technology company Becton Medical and NanoString jointly announced that they will start a strategic cooperation in the field of single-cell spatial multiomics, combining the advantages of both parties to provide one-stop technical tools and services for domestic basic scientific research, clinical research and biomedical research and development.
-
Jiangxi Province does a good job in the management of medical insurance payment for traditional Chinese medicine tablets
Time of Update: 2023-01-01
Medical security bureaus of districted cities and relevant designated medical institutions: Standardize and improve the medical insurance payment management of traditional Chinese medicine pieces in
